MVT Biotechnology Vaccine primary target:
- a newly designed vaccine directed against HEV for prophylaxis
For the development of a vaccine, MVT will develop a novel vaccine with proprietary technology to provide prophylaxis against Hepatitis E Virus.
To date, no approved vaccine is available in Europe or the US for prophylaxis of hepatitis E, (only one vaccine against HEV is available in China), and no therapeutic to treat an infection by this virus is available. In addition, the Chinese-territory-limited vaccine, (trade name Hecolin®), is not recommended by the WHO for global distribution, due to insufficient data. Given the global increase in yearly infections due to hepatitis E, and severe global health burden, there is a clear unmet medical need, and therefore a market available for exploitation.